Coherus Biosciences, INC 8-K filings

Coherus BioSciences has granted Apotex exclusive rights to commercialize toripalimab in Canada, securing an upfront payment and potential future milestone and sales payments.

Coherus BioSciences has sold its YUSIMRY franchise to Hong Kong King-Friend Industrial Company Ltd. for $40 million in an all-cash deal, completed on June 26, 2024.

Coherus BioSciences has appointed Rita A. Karachun, a former SVP and Global Controller at Merck, to its Board of Directors, effective May 31, 2024.

Coherus BioSciences held its 2024 Annual Meeting of Stockholders, electing three Class I directors, ratifying its accounting firm, and approving executive compensation and an equity incentive plan amendment.

Coherus BioSciences has entered into a revenue participation right purchase and sale agreement and a senior secured term loan facility, securing new financing.

Coherus BioSciences announced positive first quarter 2024 financial results, highlighted by a significant increase in revenue and the successful launch of LOQTORZI.

Coherus BioSciences has entered into a new $38.7 million term loan facility and sold revenue participation rights for $37.5 million to refinance existing debt and bolster its financial position.

Coherus BioSciences divested its ophthalmology franchise, reduced its workforce by 30%, and reported full year 2023 financial results, highlighting a strategic shift towards oncology.

Coherus BioSciences has completed the divestiture of its ophthalmology franchise, including CIMERLI, to Sandoz for $170 million in upfront cash, plus $17.8 million for inventory and prepaid assets.

Coherus BioSciences has expanded its board of directors by appointing Georgia Erbez as a Class III director, effective February 20, 2024.

Coherus BioSciences has amended its loan agreement with Pharmakon Advisors, LP, allowing for a $175 million debt reduction following the sale of its ophthalmology business to Sandoz.

Coherus BioSciences has agreed to sell its ophthalmology business, including CIMERLI, to Sandoz for $170 million in cash, plus inventory value and adjustments.